Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRII-179, BRII-835, and PEG-IFNα in Chronic Hepatitis B Virus Infection (ENRICH)
NCT06491563Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Recombinant Protein Vaccines, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BRII-179 and elebsiran in chronic hepatitis B virus infection (CHB) (2 arms), sponsored by Brii Biosciences. Primary endpoint: Percentage of participants achieving HBsAg seroclearance. Started Aug 2024; status: completed.
02
Drugs
BRII-179elebsiran
03
Conditions
chronic hepatitis B virus infection (CHB)
Beyond the preview
Go deeper on NCT06491563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491563.